7/7/2010

Shire obtained FDA approval to market its Daytrana skin patch to treat patients ages 13 to 17 with attention-deficit/hyperactivity disorder. The treatment, which contains methylphenidate, previously was approved for those ages 6 to 12.

Related Summaries